Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Phase I, Open Label, Non-randomised, Non-comparative, Multi-center Study, Evaluating S65487, a Bcl-2 Inhibitor Intravenously Administered, in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Sponsor: ADIR, a Servier Group company
Terminated
The study was prematurely terminated on 14th March 2023 for strategic considerations due to the limited efficacy seen with this treatment in monotherapy. This decision was not based on any safety concerns.
Other terminated trials from ADIR, a Servier Group company
Other Relapsed or Refractory Acute Myeloid Leukemia trials with similar outcome
Browse all Relapsed or Refractory Acute Myeloid Leukemia trials
This PHASE1 trial investigates Relapsed or Refractory Acute Myeloid Leukemia and Relapsed or Refractory Chronic Lymphocytic Leukemia and is currently terminated or withdrawn. ADIR, a Servier Group company leads this study, which shows 17 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
17 versions recorded-
Nov 2024 — Present [monthly]
Terminated PHASE1
Status: Completed → Terminated
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
May 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 12 earlier versions
-
Mar 2023 — May 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2023 — Mar 2023 [monthly]
Recruiting PHASE1
-
May 2022 — Jan 2023 [monthly]
Recruiting PHASE1
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE1
-
Mar 2021 — Apr 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Oct 2020 — Dec 2020 [monthly]
Recruiting PHASE1
-
Mar 2020 — Oct 2020 [monthly]
Recruiting PHASE1
-
Sep 2019 — Mar 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE1
-
Dec 2018 — Jun 2019 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- ADIR, a Servier Group company
- Institut de Recherches Internationales Servier
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Lille, France , London, United Kingdom , Madrid, Spain , Manchester, United Kingdom , Melbourne, Australia , Nantes, France , Newcastle, United Kingdom , Nice, France , Pamplona, Spain , Salamanca, Spain and 1 more location